ORIX to Invest in Fujita Pharmaceutical, a Leading Japanese Manufacturer of Veterinary Pharmaceuticals
Jul 04, 2016
TOKYO, Japan - July 4, 2016 - ORIX Corporation ("ORIX"), a leading integrated financial services group, today announced that it intends to make an equity investment in Fujita Pharmaceutical Co., Ltd. ("Fujita Pharmaceutical"), a leading Japanese manufacturer of veterinary pharmaceuticals. ORIX plans to acquire 100% of total outstanding shares of Fujita Pharmaceutical by around the end of July 2016.
Fujita Pharmaceutical is an independent pharmaceutical company that develops, manufactures and markets pharmaceuticals for cows, pigs, chickens, and other livestock as well as pet dogs and cats. Founded in 1930, it now boasts the top domestic sales share of generic pharmaceuticals for animals, such as antimicrobial agents and antibiotics, based on its research and development, as well as manufacturing knowhow developed over many years. It maintains industry-leading productivity and compliance systems by conducting integrated management of manufacture through to sales, through the effective use of IT.
While maintaining Fujita Pharmaceutical's management independence, ORIX will help further increase its corporate value through measures to support its overseas expansion, especially in Asia. Furthermore, in April this year, ORIX invested in Kyoto Biken Laboratories, Inc. ("Kyoto Biken"), which is Japan's leading manufacturer and marketer of veterinary vaccines. In the future, ORIX aims to fully leverage the sales network developed by Fujita Pharmaceutical over many years, as well as Kyoto Biken's ability to provide solutions using data from antibody tests etc., to form Japan's leading corporate group with an integrated pharmaceutical manufacturing capability in veterinary pharmaceuticals from therapeutic drugs to preventative drugs.
Fujita Pharmaceutical and Kyoto Biken will lead the veterinary pharmaceutical industry by building a stable supply structure for a broad range of products, through the development of new products, services, and administration programs made possible by cooperation from a research and development perspective, as well as through mutual sharing of sales networks.
Also, using this corporate group as a platform, ORIX will actively pursue further investment and alliances in fields that are peripheral to veterinary pharmaceuticals, and to become a total service provider that can respond to previously unmet medical needs by combining the preventative and therapeutic knowhow of the corporate group in the livestock and domestic pet industries, and to contribute to further growth and progress of the Japanese industry.
Going forward, ORIX will draw on the expertise it has developed thus far to support the growth of companies with stable business platforms, high-quality technologies and services, and further growth potential.
|Company name||Fujita Pharmaceutical Co., Ltd.|
|Address||2-13-2 Kamiosaki, Shinagawa-ku, Tokyo|
|Business locations||3 domestic locations
(head office, Tokyo factory, Kuroiso factory)
|Number of employees||115 (as of December 31, 2015)|
|Business scope||Manufacture, import and marketing of veterinary
pharmaceuticals, veterinary quasi-pharmaceuticals, feed,
and feed additives, import and marketing of
veterinary medical equipment, and marketing of physical
and chemical apparatus, as well as dairy machinery and tools
|Revenue||Approx. 5.5 billion yen (year ended November 2015)|
|Company name||Kyoto Biken Laboratories, Inc.|
|Address||24-16 Makishima-cho, Uji City, Kyoto|
|Business locations||5 domestic locations
(main factory, second research laboratory, logistics center,Miyazu branch, Sapporo office);1 overseas location (Vietnam)
|Number of employees||258 (as of October 31, 2015)|
|Business scope||Research and development, manufacturing, marketing, import and export of biological products and drugs for animals and plants|
|Revenue||Approx. 6 billion yen (year ended December 2015)|
Corporate Planning Department
ORIX Corporation (TSE: 8591; NYSE: IX) is a financial services group which provides innovative products and services to its customers by constantly pursuing new businesses. Established in 1964, from its start in the leasing business, ORIX has advanced into neighboring fields and at present has expanded into the lending, investment, life insurance, banking, asset management, automobile-related, real estate and environment and energy-related businesses. Since its first overseas expansion into Hong Kong in 1971, ORIX has spread its business globally by establishing locations in a total of 37 countries and regions across the world. Moving forward, ORIX aims to contribute to society while continuing to capture new business opportunities. For more details, please visit our website: http://www.orix.co.jp/grp/en/
Caution Concerning Forward Looking Statements:
These documents may contain forward-looking statements about expected future events and financial results that involve risks and uncertainties. Such statements are based on our current expectations and are subject to uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that could cause such a difference include, but are not limited to, those described under "Risk Factors" in the Company's annual report on Form 20-F filed with the United States Securities and Exchange Commission and under "4. Risk Factors" of the "Summary of Consolidated Financial Results" of the "Consolidated Financial Results April 1, 2015 - March 31, 2016.
- View PDF of this release